Hopebridge and Akiva Partner for Virtual Reality Additive Design Clinical Pilots

One-of-a-kind research to advance the therapeutic benefits of applied behavior analysis and autism therapies

Hopebridge uses virtual reality to advance therapy

Child using virtual reality headset
Child using virtual reality headset

Indianapolis, Nov. 21, 2022 (GLOBE NEWSWIRE) — Hopebridge Autism Therapy Centers, the nation’s largest autism therapy healthcare provider, is advancing autism spectrum disorder (ASD) research with new groundbreaking virtual reality additive design drivers. Hopebridge clinical pilots will implement virtual reality in applied behavior analysis (ABA therapy) programs at multiple centers across the country.

Hopebridge pilots will use Akiva, an immersive virtual reality learning experience that combines play with artificial intelligence to create a predictable learning ecosystem that enables children with special needs to develop sensory, cognitive, perceptive and fine. Hopebridge’s use of Akiva through Oculus Quest VR headsets will allow clinicians to monitor and record the additive benefits of VR combined with Applied Behavior Analysis (ABA) therapy to improve the rate of skill acquisition behavior in children with autism.

The study is led by Hopebridge Scientific Director, Dr. Adam Hahs. “Virtual reality holds tremendous potential to enhance and enhance the way we provide care to our patients,” Dr. Hahs said. “Our partnership with Akiva demonstrates our commitment to innovation and the growing digital therapeutic market. Our clinicians are empowered to use technology, infrastructure, and customized research solutions to accelerate early interventions critical to patient development.

Although the applicability of virtual reality has never been questioned, its scope will soon be realized given the recent announcement of a billing code for services offering this opportunity to families. With virtual reality payer recognition, families will be able to access ABA treatment that is the benchmark in the healthcare vertical.

Clinical pilots with Akiva will focus on studying an in-center VR therapy program, with Akiva software collecting patient data and outcomes. The cloud-based software will provide real-time data tracking for clinical outcomes, including:

  • Label objects, numbers and letters
  • Speech production and articulation
  • Social abilities
  • Vestibular and proprioceptive awareness
  • Eye tracking and joint attention
  • Response speed (latency)

“At Akiva, our vision is to enable neurodivergent people to learn, self-explore, and thrive by developing their unique abilities,” said Akiva CEO Alexander Landa. “The proliferation of virtual reality and machine learning has expanded the ways in which companies like Hopebridge can deliver safe, immersive and fun care to recipients, while objective, data-driven improvements are shared with all members. of the ecosystem. Akiva is working closely with Hopebridge to refine and expand the platform functionality blueprint that will revolutionize early intervention.

Tracking data for the phase one pilots will inform the execution and delivery of phase two, which is a large-scale randomized controlled trial (RCT) to be launched across Hopebridge’s footprint in 2023.

In March, the organization announced a new clinical division with leadership appointments to support initiatives to improve clinical outcomes and a growing value model of care. Dr. Hahs has been named chief scientific officer of the organization, responsible for leading the multi-state organization toward improved clinical outcomes, value-based healthcare, research initiatives and clinical innovation.

Dr. Hahs also leads Hopebridge’s participation in the International Consortium for Health Outcomes Measurement (ICHOM), as well as leading exclusive continuing education opportunities for clinicians like PEAK training. Hahs has been instrumental in developing one of the largest clinical oversight programs in the industry, the Hopebridge Fellowship Program, as well as driving strategies for major internal and external research initiatives in the field. behavioral health.

For more information on Hopebridge Centers and Services, visit hopebridge.com/centers.


About Hopebridge

Hopebridge was founded in 2005 to meet the growing need for autism treatment services and to improve the lives of affected children and families. Hopebridge is committed to providing personalized outpatient ABA, occupational therapy, speech therapy and nutrition therapies for children affected by autism spectrum disorders and behavioral, physical, social, communication and sensory challenges. Hopebridge provides a place of trust where they can receive the care, support and hope they deserve.

More than a decade later, Hopebridge continues to open state-of-the-art autism treatment centers in new communities to reach patients and families in need of services. Headquartered in Indianapolis, Hopebridge operates more than 100 centers in the following twelve states: Alabama, Arizona, Arkansas, Colorado, Florida, Georgia, Indiana, Kentucky, North Carolina, Oklahoma, Ohio and Tennessee.


  • Hopebridge uses virtual reality to advance therapy
CONTACT: Samantha Sandala Hirons (608) 575-2784 ssandala@hirons.com 

Disclaimer: The above press release is provided to you under an agreement with GlobeNewswire. IndiaShorts does not take any editorial responsibility for the same.

Leave a Reply

%d bloggers like this: